Abstracts Archive - Page 141 of 2607 - ACR Meeting Abstracts

Abstract Number: 0062 • ACR Convergence 2025
Neddylation as a Therapeutic Target in Autoimmune Arthritis: Evidence from SKG Mice
Sho Sendo¹, Alfonso Del Peral Fanjul², Kazuma Nishisaka², Hirotaka Yamada¹, Takaichi Okano¹, Keisuke Nishimura¹, Yo Ueda¹ and Jun Saegusa², ¹Kobe University Hospital, Kobe, Japan, ²Kobe University, Kobe, Japan
Background/Purpose: Neddylation, NEDD8 conjugating process, is a post-translational modification that plays a crucial role in regulating ubiquitination by targeting cullin (CUL)-ring E3 ubiquitin ligases. Our…
Abstract Number: 2283 • ACR Convergence 2025
Arrhythmia Risk in Diabetic Rheumatoid Arthritis Patients: Comparative Analysis of IL-6 Inhibitors versus TNF-α Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure², Gurjot Singh³, Kim Nguyen³, Nirys Mateo Faxas⁴, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: Background: Both rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) are independently associated with increased cardiovascular risk, including cardiac arrhythmias. The impact of…
Abstract Number: 0124 • ACR Convergence 2025
Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome
Haoyu Pan¹, Shiyan Gu¹, Xiaohan Wei², Yuying Fan¹, Jinyi Qian¹, Shuyi Yu¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying Talitacicept therapy in primary antiphospholipid syndrome (PAPS) patients using integrated single-cell RNA and TCR/BCR profiling of…
Abstract Number: 0186 • ACR Convergence 2025
Validation of Asynchronous Telehealth Visit for Adults and Children with Inflammatory Arthritis and Feasibility of Applying Thermal Imaging during Visits
Jenna Thomason¹, Rajdeep Pooni², Erin Sullivan³, Adriel Liau³, Sadie Van den Bogaerde¹, Iris Hamilton³, Sriya Paluvayi³, Megan Tran⁴, Janeth Robles-Navarro⁴, Ian Muse⁵, Audrey Luey⁴, Ava Klein³, Debosmita Biswas⁴, Savannah Partridge⁴, Tzielan Lee⁶, Alison Bays¹, Grant Hughes⁷, Elizabeth Ferucci⁸ and Yongdong (Dan) Zhao⁹, ¹University of Washington, Seattle, WA, ²Stanford University, Berkeley, CA, ³Seattle Children's Hospital, Seattle, ⁴University of Washington, Seattle, ⁵University of Washington, Department of Pediatrics, Seattle Children's Hospital, Seattle, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷University of Washington, Lynnwood, WA, ⁸Alaska Native Tribal Health Consortium, Anchorage, AK, ⁹Seattle Children’s Research Institute, Redmond, WA
Background/Purpose: Use of telemedicine has increased substantially. Our overall goal was to assess the utility of a standardized video joint exam and infrared thermal imaging…
Abstract Number: 0184 • ACR Convergence 2025
Neurocognitive Complications of Lupus: A Multidisciplinary Program Model for Advanced Diagnostics, Management, and Clinical Research
Douglas Wilcox¹, Matthew Baum², Sophie Lebiedz², John Sullivan², Margaret Naclerio², Jonathan Zurawski², Bonnie Glanz², Rohit Bakshi², Tanuja Chitnis², Shamik Bhattacharyya³ and Karen H. Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Malden, MA, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Neurological symptoms in lupus are common and occur in the majority of patients with SLE. Although neuropsychiatric lupus (NPSLE) can involve the entire nervous…
Abstract Number: 0151 • ACR Convergence 2025
Post-COVID Decline in Systemic Lupus Erythematosus Mortality in the United States: A National Analysis from 2014 to 2023
Ghassan Makhoul¹, Aziz-ur-Rahman Khalid², Islam Rajab¹, Hasan Munshi¹, Emmanuel Olumuyide³, MD Walid Akram Hussain¹, Aqsa Sorathia¹, Reshma John¹, Ahmed Huzien¹, ivan Mercado¹, Nargis Mateen⁴ and Robert Lahita², ¹St. Josephs University Medical Center, Paterson, ²St. Josephs University Medical Center, Wayne, NJ, ³Advocate Illinois Masonic Medical Center, Chicago, ⁴St. Josephs University Medical Center, Paterson, NJ
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with high morbidity and mortality. The impact of the COVID-19 pandemic on SLE-related deaths…
Abstract Number: 0176 • ACR Convergence 2025
Development and Validation of an Accurate Patient Reported Outcome Measure-based Disease Activity Score to Enable Remote Monitoring in RA
Agnes Looijen¹, Paco Welsing², Sytske Anne Bergstra³, Annette van der Helm-van Mil³ and Pascal de Jong⁴, ¹Erasmus MC, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, ³LUMC, Leiden, Netherlands, ⁴Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands
Background/Purpose: For RA patients, regular monitoring of disease activity is essential, but in-person assessments may not always be feasible due to the increasing pressure on…
Abstract Number: 0201 • ACR Convergence 2025
Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
Ana Victoria Esteban Vázquez¹, Martina Steiner², Cristina Vergara², Elisabet Castañeda Estévez³, Maria Beatriz Paredes Romero⁴, Isabel De La Camara-Fernandez¹, Laura Trives¹, Tatiana Cobo¹, Patricia Richi⁵, Maria liz Romero⁵, Marta De San Segundo³, Antonio Sanchis³, Carolina Marín⁶, Maria Teresa Navio Marco⁷ and Santiago Muñoz¹, ¹Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ²Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Madrid, Spain, ³Hospital Universitario Infanta Sofía, Madrid, Spain, ⁴Infanta Sofía University Hospital, Madrid, Spain, ⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de Los Reyes, Madrid, Spain, ⁶Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁷Infanta Leonor Universitary Hospital, Madrid, Spain
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) receiving Janus Kinase Inhibitors (JAKi) are at increased risk of herpes zoster reactivation. The adjuvanted recombinant zoster vaccine…
Abstract Number: 0014 • ACR Convergence 2025
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Mira Tohmé, Meriam Vejiga, Wendy Yu, Emily Kang, Katharine Yu, Jessica Sood, Ivan Chan, Kyle Hansen, David Shook and Phung Gip, Nkarta, South San Francisco, CA
Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…
Abstract Number: 0204 • ACR Convergence 2025
Immunogenicity and safety summary for the chikungunya virus-like particle vaccine development programme
Lauren Tindale¹, Jason Richardson¹, Deborah Anderson¹, Jason Mendy², Sufia Muhammad², Tobi Loreth¹, Victoria Jenkins³, Krystal Valenzuela⁴, Benedetto Simone⁵, Patrick Ajiboye² and Lisa Bedell⁴, ¹Bavarian Nordic Canada Inc., Toronto, Canada, ²Bavarian Nordic, Inc., San Diego, ³Bavarian Nordic Belgium, Brussels, Belgium, ⁴Bavarian Nordic, Inc., Durham, ⁵Bavarian Nordic Berna GmbH, Thoerishaus, Switzerland
Background/Purpose: Chikungunya virus (CHIKV) is a threat to public health and a risk for travellers to endemic countries. Typical acute symptoms include fever, arthralgia, myalgia,…
Abstract Number: 0188 • ACR Convergence 2025
Investigating Canadians’ information needs related to lupus: A Google Trends analysis of online search query data
Taylor Williamson¹, Emily Shantz¹, Susan Elliott¹, Christine Sperling², Karen H. Costenbader³ and May Choi⁴, ¹University of Waterloo, Waterloo, Canada, ²None, Calgary, Canada, ³Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ⁴University of Calgary, Calgary, AB, Canada
Background/Purpose: A lack of knowledge surrounding SLE has been identified as a main challenge for patients, particularly those seeking a diagnosis or recently diagnosed. Subsequently,…
Abstract Number: 0005 • ACR Convergence 2025
LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells
Fengxia Li¹, Jianming Sun¹, Hailin Wang¹, Yan Zhu¹, Xiaoxiao Liu¹, Jing Li¹, Yurong Qin¹, Guojin Wu¹, Jing Guan¹, Min Chen¹, Jordan Zhu², Xiaoqiang Kang¹, Xiao Huang¹ and Hong Ling¹, ¹Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Blood dendritic cell antigen 2 (BDCA2) is specifically expressed on pDCs whose uncontrolled production of type I IFN play a crucial role in the…
Abstract Number: 0109 • ACR Convergence 2025
Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation
Juan Liang¹ and Yinlian Zhang², ¹Gempharmatech, Nanjing, Jiangsu, China, ²GemPharmatech, Nanjing, China (People's Republic)
Background/Purpose: Psoriatic arthritis (PsA), a complex inflammatory disorder that affects up to 30% of psoriasis patients. It is marked by clinical heterogeneity and a lack…
Abstract Number: 0099 • ACR Convergence 2025
Time course and impact of IL17A on hepatic inflammation and fibrosis in adjuvant induced arthritis
Arthur Dollinger¹, Frédéric Meyer¹, Hélène Martin², Céline Delougeot³, Delphine Weil-Verhoeven¹ and Frank Verhoeven⁴, ¹CHU Besancon, Besancon, France, ²Université Marie et Louis Pasteur, Besancon, France, ³université Marie et Louis Pasteur, Besancon, ⁴CHU de Besançon, Besançon, Franche-Comte, France
Background/Purpose: The management of spondyloarthritis. (SpA) includes controlling disease activity as well as comorbidities such as metabolic syndrome. Metabolic syndrome can be associated with metabolic…
Abstract Number: 0097 • ACR Convergence 2025
Aberrant histone marks increase the inflammatory phenotype of rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) by suppressing NUB1 induction
Yosuke Ono¹, Camilla R.L. Machado², Eunice Choi¹, Wei Wang¹, David Boyle¹ and Gary Firestein², ¹University of California, San Diego, San Diego, ²University of California, San Diego, San Diego, CA
Background/Purpose: Fibroblast-like synoviocytes (FLS) play a central role in cartilage destruction and cytokine production in rheumatoid arthritis (RA). Neddylation, a post-translational modification involving NEDD8 conjugation,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].